RECRUITING Not applicable ClinicalTrials.gov

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • ClinicalTrials.gov ID: NCT04849754

Registry updated: 2026-08-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

Interventions

bone scintigraphy (Diagnostic test)
Bone scintigraphy

Eligibility criteria

Inclusion Criteria: * Patient, male or female, over 18 years of age * Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * Patient with signed consent Exclusion Criteria: * Patients with systemic AL amyloidosis * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman

Conditions

Cardiac Amyloidosis

Locations

Hôpital privé Le Bois — Lille, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment